In addition, there is the additional therapy target, early vascular failure, recently pointed out [18,19,23,24,27,28,29,31,37,38,39,40], and the upgrading of the minor vessel to take over the function of the disable major vessel, competing with the Virchow triad circumstances devastatingly present, making possible the recruitment of collateral blood vessels also in isoprenaline rats [38]
Nausea is by far the most common side effect, appearing in roughly 5070% of users, especially during the early stages of treatment
Discontinuation due to drug-related treatment-emergent adverse reactions occurred in 1.3% of the MOXATAG-treated patients and 3.3% of the penicillin VK-treated patients
longer-term safety data are not yet available Phase 3 trials are ongoing and will provide more comprehensive data on long-term safety, cardiovascular outcomes, and quality of life